Molecular testing including an Oncomine assay confirmed MYCN-amplified anaplastic ependymoma portending a poor prognosis.7 In June 2018, he demonstrated interval growth of a dorsal T9–10 lesion with worsening lower-extremity weakness, along with bowel and bladder dysfunction and underwent a T9–10 laminectomy and tumor resection. The gene discussed is MYCN; the disease is anaplastic ependymoma.